Physician profile
Jody Reiser
NPI 1194949560
$2,113.86
in general payments reported to CMS, 2019-2025
11 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2021: $190 · 2022: $235 · 2023: $503 · 2024: $655 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $929.56 | 2022-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $254.94 | 2022-2024 | Crexont, Rytary |
| Abbvie INC. | $253.35 | 2023-2025 | |
| Ucb, INC. | $151.16 | 2023-2025 | Briviact |
| Genentech USA, INC. | $148.69 | 2019 | |
| Argenx US, INC. | $138.86 | 2024 | Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $111.12 | 2021 | |
| Sk Life Science, INC. | $79.30 | 2021 | |
| Neurocrine Biosciences, INC. | $27.95 | 2019 | |
| Allergan, INC. | $13.84 | 2019 | |
| Sumitomo Pharma America, INC. | $5.09 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Reiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.